Related Experiment Video
Updated: May 8, 2026

06:45
Determining Surface Areas and Pore Volumes of Metal-Organic Frameworks
Published on: March 8, 2024
Beyond Porosity: Reframing Metal-Organic Frameworks in Biomedicine as Dynamic, Biologically Active Materials
1Department of Chemistry and Biochemistry, The University of Texas at Dallas, 800 West Campbell Road, Richardson, Texas 75080, United States.
ACS Applied Materials & Interfaces
|May 6, 2026
Summary
Biomedical metal-organic frameworks (MOFs) are not inert carriers. Their dynamic nature, including disassembly and bioactivity, actively shapes biological outcomes, requiring new engineering approaches.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Coordination Chemistry
Background:
- Metal-organic frameworks (MOFs) possess permanent porosity, initially making them attractive for biomedical applications like drug delivery.
- The prevailing view considered MOFs as passive carriers for cargo loading, protection, and release.
Purpose of the Study:
- To challenge the notion of biomedical MOFs as biologically inert carriers.
- To highlight the dynamic and programmable nature of MOFs in biological environments.
- To propose a shift towards engineering MOFs that leverage their inherent bioactivity.
Main Methods:
- Conceptual analysis of MOF behavior in biological settings.
- Examination of MOF properties including coordinated disassembly, particle transport, and framework-derived activity.
- Evaluation of MOF performance beyond traditional metrics like surface area and pore volume.
Main Results:
- Biomedical MOFs are metastable, dynamic coordination materials, not inert carriers.
- MOF composition, structure, and environmental transformations significantly influence biological outcomes.
- MOF performance is poorly described by surface area, pore volume, and loading capacity alone.
Conclusions:
- MOF bioactivity, including disassembly and compositional effects, should be embraced and engineered.
- Future biomedical MOF development should focus on dynamic materials that actively shape biological responses.
- This paradigm shift moves beyond passive delivery systems to programmable therapeutic agents.

